StockNews.AI
EXAS
StockNews.AI
197 days

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

1. Exact Sciences will report Q4 2024 results on February 19, 2025. 2. Management will discuss financial performance and business updates via a webcast. 3. The company focuses on cancer screening and diagnostic innovations. 4. Exact Sciences aims to enhance clarity in cancer diagnosis and care. 5. Webcast open to all interested parties, extends company transparency.

Earnings
-1.45%Current Return
VS
-0.67%S&P 500
$56.0502/03 06:18 AM EDTEvent Start
$55.2402/03 08:10 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Earnings reports are routine; no new catalysts are indicated in this announcement.

How important is it?

The announcement signals important earnings information, yet lacks groundbreaking news.

Why Short Term?

Upcoming results could reveal insights but are not expected to drive long-term trends.

Related Companies

EXAS
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date:  Wednesday, February 19, 2025 Time:  5 p.m. ET Webcast:  The live webcast can be accessed at www.exactsciences.com Telephone:  Domestic callers, dial 888-330-2384  International callers, dial +1 240-789-2701 Access code for both domestic and international callers: 4437608  A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Related News